Merck & Moderna's Cancer Vaccine Shows Promising Results in Late-Stage Trial

A major breakthrough in cancer treatment has been announced by Merck & Co. and Moderna Inc., with their mRNA cancer vaccine showing promising results in a late-stage trial.

The study, which combined the personalized mRNA-based vaccine intismeran with immunotherapy Keytruda, demonstrated that patients treated with both medications had a significant reduction in melanoma recurrence.

The results of this trial are crucial for proving the effectiveness of cancer vaccines and paving the way for their use in treating other types of cancer.